Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer

Roy S. Herbst, David H. Johnson, Eric Mininberg, David P. Carbone, Ted Henderson, Edward S. Kim, George Blumenschein, Jack J. Lee, Diane D. Liu, Mylene T. Truong, Waun K. Hong, Hai Tran, Anne Tsao, Dong Xie, David A. Ramies, Robert Mass, Somasekar Seshagiri, David A. Eberhard, Sean K. Kelley, Alan Sandler

Research output: Contribution to journal › Article › peer-review

557 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer'. Together they form a unique fingerprint.

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer

Fingerprint

Medicine & Life Sciences